To augment host response. True efficacy is difficult to ascertain as given with other treatments. As a result, the data are conflicting, with one study showing no increase in survival [6/38 (21%) with G-CSF versus 2/9 (22%) in those who were not given G-CSF] and another reporting survival in 83% of cases of mucormycosis. The gene discussed is CSF3; the disease is Zygomycosis.